Pharmaceutical companies Impax Laboratories Inc. and CorePharma, LLC have agreed to divest all of CorePharma’s rights and assets to generic pilocarpine tablets and generic ursodiol tablets, in order to settle Federal Trade Commission charges that Impax’s proposed $700 million acquisition of CorePharma would likely be anticompetitive. Perrigo Company plc, a global drug company headquartered in […]
Tag Archives: Health Care Prescription Drugs Bureau of Competition Competition Merger
FTC Puts Conditions on Sun Pharmaceutical’s Proposed Acquisition of Ranbaxy
Pharmaceutical companies Sun Pharmaceutical Industries Ltd. and Ranbaxy Laboratories Ltd. have agreed to divest Ranbaxy’s interests in generic minocycline tablets in order to settle Federal Trade Commission charges that Sun’s $4 billion proposed acquisition of Ranbaxy would likely be anticompetitive. Torrent Pharmaceuticals Ltd., a global drug company based in India that markets generic drugs in […]
FTC Puts Conditions on Akorn Enterprises’ Proposed Purchase of Hi-Tech Pharmacal
Akorn Enterprises, Inc. and Hi-Tech Pharmacal, Inc. will sell the rights and assets to three generic prescription eye medications and two generic topical anesthetics to Watson Laboratories, Inc., to settle Federal Trade Commission charges that Akorn’s proposed $640 million acquisition of Hi-Tech would be anticompetitive and lead to higher prices for consumers. The FTC […]
FTC Puts Conditions on Thermo Fisher Scientific Inc.’s Proposed Acquisition of Life Technologies Corporation
Thermo Fisher Scientific Inc. (Thermo Fisher), a leading manufacturer of products used in scientific research, has agreed to sell assets to GE Healthcare to settle Federal Trade Commission charges that its proposed $13.6 billion acquisition of Life Technologies Corporation (Life) would likely substantially lessen competition. The FTC complaint challenging the transaction alleges that the deal, […]
FTC Puts Conditions on Endo Health Solutions’ Acquisition of Boca Life Science Holdings
Pharmaceutical companies Endo Health Solutions Inc. (Endo) and Boca Life Science Holdings, LLC and Boca Pharmacal, LLC (Boca) have agreed to a settlement resolving Federal Trade Commission charges that Endo’s acquisition of Boca would be anticompetitive. Under the settlement, the companies will relinquish their rights to market and distribute four generic multivitamin fluoride drops for […]
FTC Approves Final Order Settling Charges That Mylan, Inc.’s Acquisition of Agila Specialties Global Pte. Ltd and Agila Specialties Pvt. Ltd. Was Anticompetitive
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Mylan, Inc.’s acquisition of Agila Specialties Global Pte. Ltd and Agila Specialties Pvt. Ltd. (collectively, Agila) from Strides Arcolab Ltd. was anticompetitive in 11 injectable generic drug markets. The FTC’s order, first announced in September, requires Mylan and […]
FTC Settles Charges That Actavis’s Proposed $8.5 Billion Acquisition of Warner Chilcott Would be Anticompetitive
International drug manufacturer Actavis, Inc. has agreed to sell all rights and assets to four generic pharmaceuticals – three oral contraceptives and an osteoporosis treatment – to settle FTC charges that its proposed $8.5 billion acquisition of drug-maker Warner Chilcott plc would be anticompetitive. As part of the proposed settlement, Actavis is seeking FTC approval […]
FTC Puts Conditions on Mylan’s Proposed Acquisition of Agila from Strides
The Federal Trade Commission will require Mylan, Inc., and Agila Specialties Global Pte. Ltd and Agila Specialties Pvt. Ltd. (collectively, Agila) to divest 11 generic injectable drugs as a condition of allowing Mylan’s proposed acquisition of Agila from Strides Arcolab Ltd. (Strides). According to the complaint, in each of these 11 markets, Mylan and Agila […]